Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laborato⦠read more
Healthcare
Medical Devices
1 years
USD
Exclusive to Premium users
$1.31
Price-4.75%
-$0.06
$141.563m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$4.173m
-
1y CAGR-
3y CAGR-
5y CAGR-$61.825m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.20
-
1y CAGR-
3y CAGR-
5y CAGR-$5.377m
$32.795m
Assets$38.172m
Liabilities$35.270m
Debt107.5%
-0.6x
Debt to EBITDA-$12.497b
-
1y CAGR-
3y CAGR-
5y CAGR